comprehensive -WSS

comprehensive

author：explore 2025-08-28 02:48:50 - browse：8568

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

entertainment

WSS

How redistricting in 6 states could affect who controls Congress

California man arrested in connection with serial murders of Mexican strip club workers

UPS workers' union leader explains what's at stake as strike edges closer

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

HHS secretary Becerra pressed on Change HealthCare cyberattack

UCLA team creates talking throat patch for voice disorders

focus

comprehensive

entertainment

How to save PrEP access — and even expand it

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Rare Northern Lights show in US this week: Where and how to see it

Wildfire smoke exposes gaps in outdoor worker protections

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Rare Northern Lights show in US this week: Where and how to see it

Heart attack and stroke risk calculators need revising

How corporate America is slashing DEI workers amid backlash to diversity programs

explore

US intelligence assessment says Iran not currently developing nuclear weapons

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

John Green on his newest strategy for fighting tuberculosis

How many hemophilia patients actually want gene therapy?

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

HHS secretary Becerra pressed on Change HealthCare cyberattack

hotspot

entertainment

focus

explore